古代日耳曼和阿拉伯律法与唐律中法医学内容的比较

本文详细介绍了古代日耳曼和阿拉伯律法中与法医学有关的内容及其对法医学发生发展的影响。认为以赎罪金代替原始的血亲复仇法是日耳曼法的一个进步；两法对非致命损伤的赔偿规定都取得了令人瞩目的成就。本文还就大致同时代的唐律对杀人及伤害案件的有关规定，比较了东西方法规的异同，探讨了差别的原因。     

清燥救肺汤加减治疗依那普利所致咳嗽临床研究

目的 :观察清燥救肺汤加减治疗依那普利所致咳嗽疗效。方法 :设清燥救肺汤组与复方甘草片组对照观察疗效及对血压的影响。结果 :与对照组比较 ,疗效有显著差异 ,P <0 .0 1;血压有明显改善 ,P <0 .0 5。结论 :清燥救肺汤用于治疗依那普利所致咳嗽疗效肯定。     

六味地黄汤对实验性糖尿病大鼠心、肝、肾组织中过氧化氢酶活性和过氧化脂质含量的影响

用四氧嘧啶诱导雄性Ｗｉｓｔａｒ大鼠为模型进行研究．结果发现，四氧嘧啶大鼠血糖明显升高，且心、肝、肾组织中过氧化氢酶活性较正常组明显降低，过氧化脂质含量在心、肝组织中明显增高，过氧化脂质与过氧化氢酶比值在心、肝、肾组织中均明显高于正常组，表明糖尿病状态下大鼠心、肝、肾组织中均自由基生成增多，氧化损伤加重．经六味地黄汤治疗后，血糖明显下降，但心、肝、肾组织中的过氧化氢酶活性无改变；而心肌中过氧化脂质含量和过氧化脂质与过氧化氢酶比值则明显降低，过氧化脂质含量和过氧化脂质与过氧化氢酶比值在肝、肾组织中无变化，表明六味地黄汤能明显清除心肌中自由基，抑制心肌中脂质过氧化，且此作用并不是通过提高过氧化氢酶活性来达到．     

桂枝汤各组分作用的比较

以急性毒性、镇痛及体温降低作用为指标比较了桂枝汤及其组方中五味中药的作用。证实桂枝汤的镇痛作用主要由桂皮和芍药所致；降温作用主要因桂皮和甘草所致。在方剂中各味中药可产生协同效应。桂枝汤毒性主要由桂皮和甘草所致。方剂中各药的毒性均较单独用药降低。表明桂枝汤组方后各味中药的疗效增强而毒性降低。     

胃癌组织中KAI1、nm23及P53的表达及其临床意义

目的:探讨正常胃黏膜、不典型增生胃黏膜及癌组织中KAI1、nm23及P53蛋白的表达．方法:应用SP法免疫组化检测22例正常胃黏膜,65例不典型增生胃黏膜及74N胃癌组织中的KAI1、nm23及P53蛋白的表达．结果:正常胃黏膜、不典型增生胃黏膜及胃癌组织中,KAI1和nm23阳性率呈降低趋势,组间差异性有统计学意义(x2=20．885, P<0．001;x2=29．133,P<0．05):P53蛋白阳性表达率呈增加趋势,组间差异性有统计学意义(x2=21．954,P<0．001)．Fisher精确概率检验显示:在胃癌组中不同的浸润深度、有无淋巴结转移和脉管侵犯组内KAI1、nm23及 P53组阳性表达率的差异性有统计学意义(x2 =20．885,P<0．001;x2=29．133,P<0．05;x2= 21．954,P<0．001);而在年龄、性别组间的差异性无统计学意义．Spearman等级相关分析显示 KAI1与nm23表达呈正相关(r=0．859,P<0．05); KAI1与P53表达呈负相关(r=-0．859,P<0．05), nm23与P53表达呈负相关(r=-0．874,P<0．05) 结论:抑癌基因KAI1与nm23的缺失以及P53 蛋白的过表达可能是胃癌发生、发展及浸润和转移的重要原因之一．     

糖骨康胶囊治疗糖尿病骨质疏松临床研究

目的:观察糖骨康胶囊对糖尿病骨质疏松的治疗作用。方法:将216例患者,遵照随机、盲法、对照原则分为治疗组144例、对照组72例,其中治疗组给予糖骨康胶囊,对照组给予甘露消渴丸,治疗8w后观察疗效。结果:治疗组显效率为40.0%;总有效率为88.6%。对照组显效率为28.9%,总有效率为82.6%。结论:糖骨康胶囊对2型糖尿病骨质疏松有显著的防治作用。     

Ethik in der Intensivmedizin

In more than 30 years of development of intensive care medicine (ICM), our speciality has acquired moral and ethical standpoints, although not without public pressure and discussions. Special commissions dealing, e.g., with brain death, terminal care, ethics of foregoing life-sustaining treatment in the critically ill, withholding or withdrawing mechanical ventilation, and other issues have meen formed in a number of medical societies. International consensus conferences have helped to clarify some of the issues. With increasing experience, a multitude of ethical problems have arisen in ICM that have to be dealt with, such as the issue of quality of life. What is an unworthy life? Are we allowed to make judgments for our patients? What is cost-effectiveness in ICM? Other restrictions include bed and equipment shortages in the intensive care unit (ICU), the necessity for triage – undisputed in catastrophe medicine – and how one should proceed in managing elective patients? In situations of limited ICU bed availability, sicker patients will be admitted, sparing out patients who are less ill for observation and those with poor quality of life and poor prognosis. For the future, it will likely be necessary to define the patients who should be admitted to an ICU more than those who should not be admitted. An ICU treatment entitlement index would be directly proportional to the probability of successful outcome and the quality of the remaining life, and would be inversely related to costs for achieving success. The ICU outcome with survival, hospital mortality, and follow-up of ICU patients is considered. DNR (do not resuscitate), the dying patient, terminal care, terminal weaning – DNT (do not treat) – active and passive euthanasia, living wills, quality of life, and cost-effectiveness for ICU patients are defined. Their application in the ICU will be discussed and problems pointed out. Outcome predictions using scores (APACHE III, SAPS II, MPM) have been developed based on previous experience, but should only be applied to patient groups and for quality assurance in ICUs. The most frequent and difficult problem in the ICU is the vegetative state, which requires an exact diagnosis. The differential diagnosis from other comatose states such as coma, brain death, and locked-in-syndrome is depicted. The ethics of interrupting life-sustaining treatment in critically ill patients have been worked out by a Task Force on Ethics of the Society of Critical Care Medicine (1990). A consensus was found that the patient may judge to forego therapy; ethically it is then appropriate to withhold or withdraw therapy. According to the consensus, withdrawing an already initiated treatment should not necessarily be regarded as more problematic than a decision not to initiate treatment. In my mind, however, there is a great difference between withdrawing or withholding, e.g., ventilation. A dissentive opinion by some members of the Task Force stated that hydration and nutrition other than high-technology or parenteral nutrition are key components of patient care, and should not be equated with medical intervention. The ethical problems associated with active euthanasia (physician-assisted suicide or death) as practised in the Netherlands are also discussed. In most countries this practice seems unacceptable. From 30 years experience in ICM, there are many more ethical questions and case reports without clear solutions. Care decisions for single patients in unacceptable situations should be made after medical evaluation by the intensivist with the medical team and, if possible, by the patient and/or his or her surrogate. Legislation and solutions cannot be expected for single patients, but ethics committees could be helpful in decision-making.     

仲景大小汤辨要

张仲景在《伤寒论》与《金匮要略》中，以大小成对命名方剂者共有六对。其命名的基本条件①凡名同者，其间必有联系；②大汤其药力强，治疗的病情重；小汤其药力弱，治疗的病情轻。理解仲景大小汤的含义，对理解仲景汤方命名规律及临床辨证具有重要意义。     

耳穴压豆法治疗儿童哮喘50例

采用耳穴压豆法治疗儿童哮喘５０例，并随访１年。结果：痊愈１１例；好转３７例；无效２例，总有效率为９６％。认为此法不仅能预防哮喘的发作，还能避免药物引起的副作用。     

参仙汤改善多发性脑梗塞性痴呆大鼠学习记忆及其作用机制研究

目的：观察中药复方参仙汤对多发性脑梗塞性痴呆（简称MID）大鼠学习记忆的影响,并对其抗自由基损伤机制进行研究。方法：采用经左心注射 0.25 ml/kg 液体石蜡栓子造成 MID 大鼠模型,以水迷宫为学习记忆评价指标。通过对大鼠脑、肝组织超氧化物歧化酶（SOD）活力、丙二醛（MDA）和脂褐素（LF）含量测定,探讨参仙汤对抗脑缺血再灌注损伤的自由基损伤机制。结果：参仙汤大、中剂量组大鼠在水迷宫实验中作业时间、正确数得到提高（第5天,P<0.05 或P<0.001）。参仙汤大、中、小剂量组脑、肝组织 SOD 活力均有提高,MDA 和 LF 含量均有下降,脑组织尤为明显（P<0.01或P<0.001）。结论：参仙汤可能是通过抗脑缺血再灌注之自由基损伤,达到改善MID大鼠学习记忆功能的。